• PolyPid posted a net loss of USD 7.7 million for the three months ended March 31, 2026, narrowing from USD 8.3 million a year earlier; loss per share improved to USD 0.35 from USD 0.70.
• R&D expense edged down to USD 5.8 million from USD 6.1 million, while general and administrative costs rose to USD 1.6 million from USD 1.2 million.
• Cash, cash equivalents, and short-term deposits fell to USD 10.9 million at March 31 from USD 12.9 million at Dec. 31, with operations funded into the second half of 2026.
• Rolling NDA submission to FDA for D-PLEX100 began March 30, with completion expected imminently; FDA granted a small business waiver of about USD 4.3 million in PDUFA fees.
• U.S. commercial partnership talks for D-PLEX100 moved into late stages, with an EU filing targeted for the third quarter of 2026 and a PDUFA action date expected in the first quarter of 2027 after NDA acceptance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PolyPid Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130730PRIMZONEFULLFEED9719248) on May 13, 2026, and is solely responsible for the information contained therein.